5 Human Clinical Studies on L-Ergothioneine: GeneIII Unveils Latest Findings in Singapore
In May 2026, at the Temasek Life Sciences Laboratory (TLL) in Singapore, GeneIII unveiled five IIT (investigator-initiated) human clinical studies on L-Ergothioneine, alongside the L-Ergothioneine Human Clinical Research and Women's Health Management white paper — developed in collaboration with the National University of Singapore (NUS) and the Temasek Life Sciences Laboratory.
In parallel at the same event, Frost & Sullivan released their Global L-Ergothioneine Industry Status and Development Trends white paper, offering an independent third-party industry analysis.
The five clinical studies cover: ovarian health, period pain, postpartum recovery, male fertility, and kidney health.
Across all five, one core finding stands out: L-Ergothioneine, a natural antioxidant that precisely reaches the cellular mitochondria, is providing evidence-based support for key health concerns at the cellular level.
Ovarian Health: AMH, E2, and FSH All Move in the Right Direction
GeneIII's clinical study (ChiCTR2500104484) followed women showing signs of diminished ovarian reserve. Each participant took 120mg of GeneIII L-Ergothioneine daily for three consecutive menstrual cycles.
After three months, three key markers improved together:
- AMH rose by an average of 36.3%
- E2 (estradiol) rose by an average of 42.8%
- FSH improved by an average of 16.2%
AMH reflects ovarian reserve, E2 reflects estrogen output, and FSH reflects how hard the brain is pushing the ovaries to work. When all three shift positively in sync, it signals more than localized improvement — the endocrine system as a whole is moving toward a more youthful, balanced state.
For women over 35, those with low AMH, those planning to conceive, or those navigating long nights and high stress, this is a research direction worth taking seriously. The study was conducted as part of GeneIII's international research collaboration with the Temasek Life Sciences Laboratory in Singapore.
Primary Dysmenorrhea: Over 8 in 10 Participants See Meaningful Improvement
GeneIII's clinical study (ChiCTR2500112557) enrolled women aged 18–35 with primary dysmenorrhea. Each participant took 120mg of GeneIII L-Ergothioneine daily for three consecutive menstrual cycles.
The results:
- Response rate: 84%
- NNT (number needed to treat): 2.0 — meaning on average, 1 in every 2 participants experienced clinically meaningful relief
- No adverse events recorded throughout the study
This is the most complete dataset among the five studies and has been publicly published. For women whose work and daily life are disrupted every month by period pain, this study offers a clear answer to a real question — managing period discomfort through daily nutrition is now backed by evidence.
Postpartum Recovery: Energy, Sleep, and Vitality Improve Together
GeneIII's clinical study (ChiCTR2500114171) followed women 0–24 months postpartum, all of whom had fully stopped breastfeeding. Each took 60mg of GeneIII L-Ergothioneine daily for one month.
After 30 days, multiple recovery indicators improved at the same time:
- Overall quality of life: +35.94%
- Physical fatigue: −27.78%
- Sleep quality: +29.24%
- Qi-blood deficiency score (TCM scale): +42.78%
- Daytime functional impairment: −44.68%
These indicators map directly to what postpartum women describe most often — constant fatigue, poor sleep, dim complexion, low daytime energy. Simultaneous improvement across all of them in just one month points to L-Ergothioneine offering systemic cellular-level antioxidant support during one of the body's most demanding recovery windows.
Male Fertility: A High-Quality Study on Sperm Vitality
GeneIII's clinical study (ChiCTR2500111625) is the most methodologically rigorous of the five — using a randomized, placebo-controlled, double-blind design, which represents the highest tier of scientific reliability in clinical research.
The study focuses on the effect of L-Ergothioneine on sperm motility–related markers. Full data is expected to be released in the near future.
Lifestyle pace, chronic stress, and oxidative stress can all affect sperm vitality. L-Ergothioneine is transported into male reproductive tissue through a dedicated transporter called OCTN-1, where it delivers cellular-level antioxidant action — a mechanistic basis worth noting for families planning to conceive.
Kidney Health: Extending the Evidence into a Major Metabolic Organ
GeneIII's clinical study (ChiCTR2500108897) is now systematically evaluating L-Ergothioneine's effect on kidney function markers. Full data will be released later.
The kidneys are one of the body's most essential metabolic organs, and oxidative stress accumulation is a core driver of long-term kidney load. Through the OCTN-1 transporter, L-Ergothioneine reaches kidney tissue precisely and delivers mitochondrial-level antioxidant action.
This study extends L-Ergothioneine's evidence base from foundational antioxidant research into a major metabolic organ — opening a new direction for long-term nutritional support of kidney health.
To see how L-Ergothioneine fits into different parts of daily life, explore 6 everyday moments where L-Ergothioneine helps.
Liver Function: Three Common Markers Improve Significantly
GeneIII's liver function study (ChiCTR2400093739) is already published on medRxiv. Participants took 60mg of GeneIII L-Ergothioneine daily for 30 days.
The results:
- ALT decreased by 21.3%
- AST decreased by 19.6%
- GGT decreased by 18.2%
- No adverse events recorded
ALT, AST, and GGT are the three most common liver function markers on routine health checkups — any one of them rising would draw a doctor's attention. Simultaneous significant improvement across all three makes this study one of the most compelling pieces of human clinical evidence currently available for L-Ergothioneine, and it laid the methodological foundation for the five studies above.
For a closer look at when different markers tend to respond, see how long L-Ergothioneine takes to work.
The International Research Network Behind These Studies
GeneIII's evidence-based research is built on a system of international academic collaboration, alongside independent third-party industry validation.
Temasek Life Sciences Laboratory (TLL) — affiliated with the National University of Singapore (NUS), TLL is one of the Asia-Pacific region's leading institutions in molecular biology and genetics. GeneIII has launched an international research collaboration with TLL focused on L-Ergothioneine and ovarian health, and co-developed the L-Ergothioneine Human Clinical Research and Women's Health Management white paper.
Professor Barry Halliwell — Distinguished Professor at NUS Yong Loo Lin School of Medicine, often called the "father of ergothioneine research." With an H-index of 171 and a lifetime achievement award from the Society for Free Radical Biology and Medicine, Professor Halliwell has entered into a strategic collaboration with GeneIII to advance foundational ergothioneine science.
Frost & Sullivan — a global independent growth consulting and industry research firm. At the same Singapore event, Frost & Sullivan separately released the Global L-Ergothioneine Industry Status and Development Trends white paper — an independent third-party industry analysis, distinct from GeneIII's clinical research.
For more on the shifts shaping this category, read how antioxidant supplements are being redefined in 2026.
You can explore the full system behind these studies on the science behind GeneIII L-Ergothioneine page.
Professor Barry Halliwell
The Product Behind These Studies: GeneIII L-Ergothioneine Capsules
The capsules used by participants in all of the above studies are GeneIII L-Ergothioneine capsules. They are produced through the same synthetic biology process, verified by third-party HPLC analysis, and manufactured under cGMP pharmaceutical-grade standards — the same system that supports the improvements observed across the clinical data.
Beyond this evidence-based foundation, GeneIII L-Ergothioneine has received an FDA "No Questions" Letter for GRAS status (GRN 001270) and a Clinicians' Choice recognition from 732 U.S. licensed physicians on the FrontrowMD platform.
For more details, visit GeneIII.
FAQ About GeneIII's L-Ergothioneine Clinical Research
Q1: What human clinical studies has GeneIII completed on L-Ergothioneine?
GeneIII has registered 8 human clinical studies on L-Ergothioneine with the Chinese Clinical Trial Registry (ChiCTR). The Singapore launch unveiled the latest progress across 5 of those directions: ovarian health, period pain, postpartum recovery, male fertility, and kidney health. The liver function study is already published on medRxiv.
Q2: What is the recommended L-Ergothioneine dosage for ovarian health?
Based on GeneIII's ovarian reserve clinical study (ChiCTR2500104484), the regimen used was 120mg daily for three consecutive menstrual cycles.
Q3: What did the L-Ergothioneine study on period pain find?
In GeneIII's primary dysmenorrhea study (ChiCTR2500112557), women aged 18–35 taking 120mg daily across three menstrual cycles showed an 84% response rate and an NNT of 2.0, with no adverse events recorded.
Q4: Can postpartum women take L-Ergothioneine?
GeneIII's postpartum recovery study (ChiCTR2500114171) followed women 0–24 months postpartum who had fully stopped breastfeeding, taking 60mg daily for one month. Self-supplementation during breastfeeding is not recommended — please consult your doctor.
Q5: What does the L-Ergothioneine liver function study show?
GeneIII's liver function study (ChiCTR2400093739), published on medRxiv, found that 60mg daily for 30 days led to a 21.3% drop in ALT, 19.6% drop in AST, and 18.2% drop in GGT — the three most common liver function markers in routine checkups.
Q6: Where can I find the full clinical research information for GeneIII L-Ergothioneine?
All 8 of GeneIII's human clinical studies are registered with the Chinese Clinical Trial Registry (ChiCTR, chictr.org.cn) and cross-listed on the WHO International Clinical Trials Registry Platform (ICTRP, trialsearch.who.int) — both publicly searchable. The published liver function study can be found on medRxiv. Full information on GeneIII's evidence-based research system is available on the science behind GeneIII L-Ergothioneine page.
